Global Meningococcal Vaccines Market-our new study reveals current trends, technological advancements, and predicted revenues
Where the Global Meningococcal Vaccines market is heading? If you are involved in this industry you must read this newly updated report. Visiongain’s report shows you the potential revenue streams to 2031, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 190+ page report provides 150+ tables, 150+ charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our study lets you assess forecasted sales at overall world market and regional level. See financial performance of companies, trends, opportunities, and revenue growth. Much opportunity remains in this growing Global Meningococcal Vaccines market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
– In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares, key player positioning, and an exhaustive product portfolio comparison of key vendors
– You find original analyses, with business outlooks and developments which would be useful to tap potential business areas for key players
– Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges, SWOT analysis), product profiles and commercial developments.
Report Scope
Global Meningococcal Vaccines market 2021-2031 is segmented on the basis of Type and Geography.
• Revenue and growth forecasts from 2021 to 2031 for the Global Meningococcal Vaccines Market by Type:
– Bivalent
– Quadrivalent
– Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Meningococcal Vaccines Market by Region:
– North America: US, Canada
– Europe: Germany, UK, Italy, France, Spain, Rest of Europe
– Asia-Pacific: China, India, Japan, Australia, Rest of Asia-Pacific
– Latin America: Brazil, Mexico, and Rest of Latin America
– Middle East & Africa: GCC, South Africa, Rest of MEA
• Our study discusses the selected leading companies that are the major players in the Global Meningococcal Vaccines industry:
– Sanofi
– Merck & Co., Inc.
– GlaxoSmithKline Plc.
– Serum Institute Of India Pvt. Ltd.
– Pfizer Inc
How the Global Meningococcal Vaccines Market report helps you
In summary, our 190+ page report provides you with the following knowledge:
– Revenue forecasts to 2031 for each of the above mentioned segments each forecasted at a global and regional level– growth of all segments on regional level helps to understand most lucrative segment.
– Revenue forecasts to 2031 for 5 regional and 10 key national markets – the report highlights market growth prospects for key countries such as the U.S., Canada, Germany, UK, France, Italy, Spain, China, Japan, and India. The report also highlights growth potential in Central & South America as well as Middle East & Africa.
– Prospects for established firms and those seeking to enter the market– including company profiles for over 10 of the major companies involved in the Global Meningococcal Vaccines market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
COVID 19 Impact & Recovery Analysis on the Market
Currently, COVID-19 (Coronavirus) is prevalent across the globe. Many companies are underway to discover a vaccine, or therapeutics which can prevent or cure the COVID-19 virus. According to the World Health Organization, as of 13th September 2020, there were over 28,637,952 confirmed cases of COVID-19, with more than 917,417 deaths, globally.
The COVID-19 disease is continuously disrupting the growth of various markets. However, the immediate effect of the pandemic is different. Some industries will register a drop in demand, various other markets will remain unchanged and display a promising growth opportunities. The healthcare centers, such as hospitals and diagnostic labs, have been investing heavily in maintaining the supply of essential equipment and drugs. Due to lockdown across the globe, people were unable to reach healthcare facilities and non-urgent procedures were advised to put hold which impacted the healthcare industry a lot.
Due to COVID 19 pandemic patients were reluctant in visiting hospitals or clinics for their treatments and preferred virtual doctor visits. Lockdown across the globe due to the pandemic led to the delay of procedures which were not urgent. These factors negatively impacted the Meningococcal Vaccines market for limited period of time. However, slowly the situation is getting back to normal everywhere and the market discussed is expected to increase in future.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Global Meningococcal Vaccines market and leading companies. You will find data, trends and predictions.
The Global Meningococcal Vaccines Market 2021-2031 report will be of value to anyone who wants to better understand the market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Global Meningococcal Vaccines industry.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Meningococcal Vaccines Market Analysis: Forecasts by Serogroup (MenACWY, MenB/BC, MenC, MenAC and MenA), Vaccine Type (Conjugate, Polysaccharide and Subcapsular) and End User (Paediatric, Adults and Travellers). PLUS Profiles of Leading Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated VISIONGAIN Reports
1.8. About VISIONGAIN
2. Introduction to the Meningococcal Vaccine Market
2.1. Meningococcal VaccineMarket Definition
2.2. Meningococcal Vaccine Serotype Submarkets Definitions
2.3. Meningococcal Type Submarkets Definitions
2.4. Meningococcal End User Submarkets Definitions
3. Meningococcal VaccineMarket Overview
3.1. Global Meningococcal Vaccine Market Size and Forecast by Region
3.2. Global Meningococcal Vaccine Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increase in occurrences of meningococcal disease
3.3.1.2. Growth in immunization programs worldwide
3.3.2. Market Restraints/Challenges
3.3.2.1. Longer duration required for vaccine production
3.3.3. Opportunities
3.3.3.1. Increase in research and development for meningococcal vaccines
3.3.4. Global Meningococcal VaccineMarket: Trends
3.3.4.1. Trend 1
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Meningococcal Vaccine Market Analysis and Forecast 2021-2031, by Vaccine Serotype (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. MenACWY
4.3. MenB/BC
4.4. MenC
4.5. MenA
4.6. MenAC
5. GlobalMeningococcal Vaccine Market Analysis and Forecast, 2021-2031 by Vaccine Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.2. Conjugate
5.3. Polysaccharide
5.4. Subcapsular
6. GlobalMeningococcal Vaccine Market Analysis and Forecast, 2021-2031 by End User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. Pediatric
6.3. Adult
6.4. Travelers
7. North America Meningococcal Vaccine Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Meningococcal Vaccine Market Size and Forecast byVaccine Serotype
7.3. North America Meningococcal VaccineMarket Size and Forecast by Vaccine Type
7.4. North America Meningococcal VaccineMarket Size and Forecast by End User
7.5. U.S. Meningococcal Vaccine Market
7.6. Canada Meningococcal Vaccine Market
8. Europe Meningococcal Vaccine Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Meningococcal VaccineMarket Size and Forecast by Vaccine Serotype
8.3. Europe Meningococcal Vaccine Market Size and Forecast by Vaccine Type
8.4. Europe Meningococcal Vaccine Size and Forecast by End User
8.5. UK Meningococcal VaccineMarket
8.6. Germany Meningococcal Vaccine Market
8.7. France Meningococcal VaccineMarket
8.8. Rest of Europe Meningococcal Vaccine Market
9. Asia Pacific Meningococcal Vaccine Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Meningococcal Vaccine Market Size and Forecast by Vaccine Serotype
9.3. Asia Pacific Meningococcal Vaccine Market Size and Forecast by Vaccine Type
9.4. Asia Pacific Meningococcal VaccineMarket Size and Forecast by End User
9.4.1. China Meningococcal VaccineMarket
9.4.2. India Meningococcal Vaccine Market
9.4.3. Japan Meningococcal Vaccine Market
9.4.4. Rest of Asia Pacific Meningococcal VaccineMarket
10. Latin AmericaMeningococcal Vaccine Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Meningococcal VaccineMarket Size and Forecast by Vaccine Serotype
10.3. Latin America Meningococcal VaccineMarket Size and Forecast by Vaccine Type
10.4. Latin America Meningococcal Vaccine Market Size and Forecast by End User
10.4.1. Brazil Meningococcal Vaccine Market
10.4.2. Mexico Meningococcal Vaccine Market
10.4.3. Rest of Latin America Meningococcal Vaccine Market
11. MEA Meningococcal Vaccine Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Meningococcal Vaccine Market Size and Forecast by Vaccine Serotype
11.3. MEA Meningococcal VaccineMarket Size and Forecast by Vaccine Type
11.4. MEA Meningococcal Vaccine Market Size and Forecast by End User
11.4.1. GCC Meningococcal Vaccine Market
11.4.2. South Africa Meningococcal Vaccine Market
11.4.3. Rest of MEA Meningococcal Vaccine Market
12. Companies in the Meningococcal Vaccine Market
12.1. Bio-Manguinhos
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2019)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2019
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2019)
12.2. Chongqing Zhifei Biological Products Co., Ltd.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2019)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2019
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2019)
12.3. GlaxoSmithKline Plc
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2019)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2019
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2019)
12.4. Hualan Biological Engineering Inc.
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2019)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2019
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2019)
12.5. Incepta Pharmaceuticals Ltd.
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2019)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2019
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2019)
12.6. Pfizer Inc.
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2019)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2019
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2019)
12.7. Sanofi S.A.
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2019)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2019
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2019)
12.8. Serum Institute Of India Pvt. Ltd
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2019)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2019
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2019)
12.9. Walvax Biotechnology Co., Ltd.
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2019)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2019
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2019)
12.10. Merck & Co., Inc.
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2019)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2019
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2019)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated VISIONGAIN Reports
VISIONGAIN Report Sales Order Form
Appendix A
About VISIONGAIN
Appendix B
VISIONGAIN report evaluation form
Table No 1 Meningococcal Vaccine Market Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 2 Meningococcal Vaccine Market Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 3 Meningococcal Vaccine Market Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 4 Meningococcal Vaccine Market Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 5 Meningococcal Vaccine Market Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 6 Meningococcal Vaccine Market Drivers & Restraints 2020
Table No 7 Meningococcal Vaccine Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 8 Meningococcal Vaccine Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 9 Meningococcal Vaccine Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 10 Meningococcal Vaccine Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 11 Meningococcal Vaccine Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 12 MenACWY Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 13 MenACWY Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 14 MenACWY Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 15 MenACWY Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 16 MenACWY Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 17 MenB/BC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 18 MenB/BC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 19 MenB/BC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 20 MenB/BC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 21 MenB/BC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 22 MenC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 23 MenC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 24 MenC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 25 MenC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 26 MenA Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 27 MenA Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 28 MenA Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 29 MenA Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 30 MenAC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 31 MenAC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 32 MenAC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 33 MenAC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 34 Meningococcal Vaccine Forecast by Vaccine Type 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 35 Meningococcal Vaccine Forecast by Vaccine Type 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 36 Meningococcal Vaccine Forecast by Vaccine Type 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 37 Meningococcal Vaccine Forecast by Vaccine Type 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 38 Meningococcal Vaccine Forecast by Vaccine Type 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 39 Conjugate Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 40 Conjugate Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 41 Conjugate Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 42 Conjugate Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 43 Polysaccharide Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 44 Polysaccharide Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 45 Polysaccharide Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 46 Polysaccharide Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 47 Subcapsular Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 48 Subcapsular Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 49 Subcapsular Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 50 Subcapsular Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 51 Meningococcal Vaccine Forecast by End-User 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 52 Meningococcal Vaccine Forecast by End-User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 53 Meningococcal Vaccine Forecast by End-User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 54 Meningococcal Vaccine Forecast by End-User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 55 Meningococcal Vaccine Forecast by End-User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 56 Pediatric Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 57 Pediatric Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 58 Pediatric Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 59 Pediatric Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 60 Adult Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 61 Adult Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 62 Adult Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 63 Adult Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 64 Travelers Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 65 Travelers Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 66 Travelers Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 67 Travelers Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 68 Regional Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 69 Regional Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 70 Regional Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 71 Regional Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 72 Regional Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 73 North America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 74 North America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 75 North America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 76 North America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 77 North America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 78 US Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 79 US Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 80 US Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 81 US Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 82 US Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 83 Canada Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 84 Canada Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 85 Canada Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 86 Canada Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 87 Canada Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 88 Europe Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 89 Europe Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 90 Europe Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 91 Europe Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 92 Europe Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 93 UK Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 94 UK Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 95 UK Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 96 UK Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 97 UK Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 98 Germany Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 99 Germany Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 100 Germany Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 101 Germany Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 102 Germany Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 103 France Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 104 France Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 105 France Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 106 France Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 107 France Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 108 Rest of Europe Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 109 Rest of Europe Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 110 Rest of Europe Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 111 Rest of Europe Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 112 Rest of Europe Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 113 Asia Pacific Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 114 Asia Pacific Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 115 Asia Pacific Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 116 Asia Pacific Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 117 Asia Pacific Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 118 Asia Pacific Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 119 Asia Pacific Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 120 Asia Pacific Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 121 Asia Pacific Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 122 Asia Pacific Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 123 China Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 124 China Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 125 China Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 126 China Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 127 China Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 128 India Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 129 India Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 130 India Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 131 India Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 132 India Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 133 India Military Aircraft Fleet (Aircraft Serotype, Number of Aircraft)
Table No 134 Japan Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 135 Japan Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 136 Japan Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 137 Japan Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 138 Japan Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 139 Japan Military Aircraft Fleet (Aircraft Serotype, Number of Aircraft)
Table No 140 RoAPAC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 141 RoAPAC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 142 RoAPAC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 143 RoAPAC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 144 RoAPAC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 145 Latin America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 146 Latin America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 147 Latin America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 148 Latin America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 149 Latin America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 150 Latin America Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 151 Latin America Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 152 Latin America Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 153 Latin America Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 154 Latin America Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 155 Brazil Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 156 Brazil Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 157 Brazil Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 158 Brazil Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 159 Brazil Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 160 Mexico Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 161 Mexico Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 162 Mexico Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 163 Mexico Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 164 Mexico Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 165 Rest of Latin America Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 166 Rest of Latin America Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 167 Rest of Latin America Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 168 Rest of Latin America Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 169 Rest of Latin America Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 170 Middle East Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 171 Middle East Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 172 Middle East Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 173 Middle East Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 174 Middle East Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 175 Middle East Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 176 Middle East Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 177 Middle East Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 178 Middle East Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 179 Middle East Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 180 GCC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 181 GCC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 182 GCC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 183 GCC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 184 GCC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 185 South Africa Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 186 South Africa Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 187 South Africa Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 188 South Africa Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 189 South Africa Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 190 Rest of MEA Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 191 Rest of MEA Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 192 Rest of MEA Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 193 Rest of MEA Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 194 Rest of MEA Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 195 Leading 10 Meningococcal Vaccine Companies (Ranking, Company, Latest Total Company Sales US $MN*, HQ)
Table No 196 Bio-Manguinhos Profile (CEO, HQ, Founded, Website)
Table No 197 Bio-Manguinhos (Total Company Sales 2016-2019 (US $Mn, AGR %)
Table No 198 Bio-Manguinhos (Net Income 2016-2019 (US $Mn, AGR %)
Table No 199 Chongqing Zhifei Biological Products Co., Ltd. Profile (CEO, HQ, Founded, Website)
Table No 200 Chongqing Zhifei Biological Products Co., Ltd. (Total Company Sales 2016-2019 (US $Mn, AGR %)
Table No 201 Chongqing Zhifei Biological Products Co., Ltd. (Net Income 2016-2019 (US $Mn, AGR %)
Table No 202 GlaxoSmithKline Plc Profile (CEO, HQ, Founded, Website)
Table No 203 GlaxoSmithKline Plc (Total Company Sales 2016-2019 (US $Mn, AGR %)
Table No 204 GlaxoSmithKline Plc (Net Income 2016-2019 (US $Mn, AGR %)
Table No 205 Hualan Biological Engineering Inc. Profile (CEO, HQ, Founded, Website)
Table No 206 Hualan Biological Engineering Inc. (Total Company Sales 2016-2019 (US $Mn, AGR %)
Table No 207 Hualan Biological Engineering Inc. (Net Income 2016-2019 (US $Mn, AGR %))
Table No 208 Incepta Pharmaceuticals Ltd. Profile (CEO, HQ, Founded, Website)
Table No 209 Incepta Pharmaceuticals Ltd. Profile (Total Company Sales 2016-2019 (US $Mn, AGR %)
Table No 210 Incepta Pharmaceuticals Ltd. Profile (Net Income 2016-2019 (US $Mn, AGR %))
Table No 211 Pfizer Inc. Profile (CEO, HQ, Founded, Website)
Table No 212 Pfizer Inc. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Table No 213 Pfizer Inc. (Net Income 2016-2019 (US $Mn, AGR %))
Table No 214 Sanofi S.A. Profile (CEO, HQ, Founded, Website)
Table No 215 Sanofi S.A. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Table No 216 Sanofi S.A. (Net Income 2016-2019 (US $Mn, AGR %))
Table No 217 Serum Institute of India Pvt. Ltd Profile (CEO, HQ, Founded, Website)
Table No 218 Serum Institute of India Pvt. Ltd (Total Company Sales 2016-2019 (US $Mn, AGR %))
Table No 219 Serum Institute of India Pvt. Ltd (Net Income 2016-2019 (US $Mn, AGR %))
Table No 220 Walvax Biotechnology Co., Ltd. (CEO, HQ, Founded, Website)
Table No 221 Walvax Biotechnology Co., Ltd. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Table No 222 Walvax Biotechnology Co., Ltd. (Net Income 2016-2019 (US $Mn, AGR %))
Table No 223 Merck & Co., Inc. Profile (CEO, HQ, Founded, Website)
Table No 224 Merck & Co., Inc. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Table No 225 Merck & Co., Inc. (Net Income 2016-2019 (US $Mn, AGR %))
Table No 226 Other Companies Meningococcal Vaccine Market 2020 (Company, Location)
Figure No 1 Meningococcal Vaccine Market Serotype Overview
Figure No 2 Meningococcal Vaccine Market End User Overview
Figure No 3 Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (Before COVID)
Figure No 4 Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario V)
Figure No 5 Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario U)
Figure No 6 Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario W)
Figure No 7 Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario L)
Figure No 8 Meningococcal Vaccine Submarket Forecast by Serotype 2020-2030 (US $MN, Global AGR %) (Before COVID)
Figure No 9 Meningococcal Vaccine Submarket Forecast by Serotype 2020-2030 (US $MN, Global AGR %) (COVID - Scenario V)
Figure No 10 Meningococcal Vaccine Submarket Forecast by Serotype 2020-2030 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 11 Meningococcal Vaccine Submarket Forecast by Serotype 2020-2030 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 12 Meningococcal Vaccine Submarket Forecast by Serotype 2020-2030 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 13 MenACWY 2020-2030 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 14 MenACWY 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 15 MenACWY 2020-2030 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 16 MenACWY 2020-2030 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 17 MenACWY 2020-2030 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 18 MenB/BC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 19 MenB/BC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 20 MenB/BC Submarket Forecast 2020-2030 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 21 MenB/BC Submarket Forecast 2020-2030 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 22 MenB/BC Submarket Forecast 2020-2030 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 23 Medical device distribution services Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 24 Medical device distribution services Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 25 Medical device distribution services Submarket Forecast 2020-2030 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 26 Medical device distribution services Submarket Forecast 2020-2030 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 27 Medical device distribution services Submarket Forecast 2020-2030 (US $MN, Global AGR %) (COVID - Scenario L)
28 MenC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 29 MenC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 30 MenC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 31 MenC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 32 MenA Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 33 MenA Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 34 MenA Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 35 MenA Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 36 MenAC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 37 MenAC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 38 MenAC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 39 MenAC Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 40 Meningococcal Vaccine Forecast by Vaccine Type 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Figure No 41 Meningococcal Vaccine Forecast by Vaccine Type 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Figure No 42 Meningococcal Vaccine Forecast by Vaccine Type 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Figure No 43 Meningococcal Vaccine Forecast by Vaccine Type 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Figure No 44 Meningococcal Vaccine Forecast by Vaccine Type 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Figure No 45 Conjugate Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 46 Conjugate Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 47 Conjugate Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 48 Conjugate Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 49 Polysaccharide Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 50 Polysaccharide Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 51 Polysaccharide Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 52 Polysaccharide Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 53 Subcapsular Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 54 Subcapsular Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 55 Subcapsular Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 56 Subcapsular Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 57 Meningococcal Vaccine Forecast by End-User 2020-2030 (US $MN, AGR %, CAGR %) (Before COVID)
Figure No 58 Meningococcal Vaccine Forecast by End-User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Figure No 59 Meningococcal Vaccine Forecast by End-User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Figure No 60 Meningococcal Vaccine Forecast by End-User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Figure No 61 Meningococcal Vaccine Forecast by End-User 2020-2030 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Figure No 62 Pediatric Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 63 Pediatric Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 64 Pediatric Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 65 Pediatric Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 66 Adult Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 67 Adult Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 68 Adult Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 69 Adult Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 70 Travelers Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 71 Travelers Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 72 Travelers Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 73 Travelers Submarket Forecast 2020-2030 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 74 Asia-Pacific Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN) (COVID - Scenario U)
Figure No 75 Asia-Pacific Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN) (COVID - Scenario W)
Figure No 76 Asia-Pacific Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN) (COVID - Scenario L)
Figure No 77 Asia-Pacific Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN)
Figure No 78 Asia-Pacific Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN) (COVID - Scenario V)
Figure No 79 Asia-Pacific Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN) (COVID - Scenario U)
Figure No 80 Asia-Pacific Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN) (COVID - Scenario W)
Figure No 81 Asia-Pacific Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN) (COVID - Scenario L)
Figure No 82 China Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %)
Figure No 83 China Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario V)
Figure No 84 China Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario U)
Figure No 85 China Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario W)
Figure No 86 China Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario L)
Figure No 87 India Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %)
Figure No 88 India Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario V)
Figure No 89 India Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario U)
Figure No 90 India Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario W)
Figure No 91 India Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario L)
Figure No 92 Japan Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (Before COVID)
Figure No 93 Japan Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario V)
Figure No 94 Japan Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario U)
Figure No 95 Japan Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario W)
Figure No 96 Japan Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario L)
Figure No 97 Rest of APAC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (Before COVID)
Figure No 98 Rest of APAC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario V)
Figure No 99 Rest of APAC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario U)
Figure No 100 Rest of APAC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario W)
Figure No 101 Rest of APAC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario L)
Figure No 102 Latin America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN)
Figure No 103 Latin America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN) (COVID - Scenario V)
Figure No 104 Latin America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN) (COVID - Scenario U)
Figure No 105 Latin America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN) (COVID - Scenario W)
Figure No 106 Latin America Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN) (COVID - Scenario L)
Figure No 107 Latin America Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN)
Figure No 108 Latin America Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN) (COVID - Scenario V)
Figure No 109 Latin America Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN) (COVID - Scenario U)
Figure No 110 Latin America Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN) (COVID - Scenario W)
Figure No 111 Latin America Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN) (COVID - Scenario L)
Figure No 112 Brazil Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (Before COVID)
Figure No 113 Brazil Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario V)
Figure No 114 Brazil Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario U)
Figure No 115 Brazil Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario W)
Figure No 116 Brazil Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario L)
Figure No 117 Mexico Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (Before COVID)
Figure No 118 Mexico Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario V)
Figure No 119 Mexico Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario U)
Figure No 120 Mexico Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario W)
Figure No 121 Mexico Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario L)
Figure No 122 Rest of Latin America Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (Before COVID)
Figure No 123 Rest of Latin Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario V)
Figure No 124 Rest of Latin Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario U)
Figure No 125 Rest of Latin Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario W)
Figure No 126 Rest of Latin Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario L)
Figure No 127 Middle East Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN) (Before COVID)
Figure No 128 Middle East Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN) (COVID - Scenario V)
Figure No 129 Middle East Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN) (COVID - Scenario U)
Figure No 130 Middle East Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN) (COVID - Scenario W)
Figure No 131 Middle East Meningococcal Vaccine Market Forecast by Serotype 2020-2030 (US $MN) (COVID - Scenario L)
Figure No 132 Middle East Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN) (Before COVID)
Figure No 133 Middle East Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN) (COVID - Scenario V)
Figure No 134 Middle East Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN) (COVID - Scenario U)
Figure No 135 Middle East Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN) (COVID - Scenario W)
Figure No 136 Middle East Meningococcal Vaccine Market Forecast by End User 2020-2030 (US $MN) (COVID - Scenario L)
Figure No 137 GCC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (Before COVID)
Figure No 138 GCC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario V)
Figure No 139 GCC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario U)
Figure No 140 GCC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario W)
Figure No 141 GCC Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario L)
Figure No 142 South Africa Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (Before COVID)
Figure No 143 South Africa Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario V)
Figure No 144 South Africa Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario U)
Figure No 145 South Africa Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario W)
Figure No 146 South Africa Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario L)
Figure No 147 Rest of MEA Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (Before COVID)
Figure No 148 Rest of MEA Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario V)
Figure No 149 Rest of MEA Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario U)
Figure No 150 Rest of MEA Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario W)
Figure No 151 Rest of MEA Meningococcal Vaccine Market Forecast 2020-2030 (US $MN, AGR %) (COVID - Scenario L)
Figure No 152 Bio-Manguinhos (Total Company Sales 2016-2019 (US $Mn, AGR %)
Figure No 153 Bio-Manguinhos (Net Income 2016-2019 (US $Mn, AGR %)
Figure No 154 Chongqing Zhifei Biological Products Co., Ltd. (Total Company Sales 2016-2019 (US $Mn, AGR %)
Figure No 155 Chongqing Zhifei Biological Products Co., Ltd. (Net Income 2016-2019 (US $Mn, AGR %)
Figure No 156 GlaxoSmithKline Plc (Total Company Sales 2016-2019 (US $Mn, AGR %)
Figure No 157 GlaxoSmithKline Plc (Net Income 2016-2019 (US $Mn, AGR %)
Figure No 158 Hualan Biological Engineering Inc. (Total Company Sales 2016-2019 (US $Mn, AGR %)
Figure No 159 Hualan Biological Engineering Inc. (Net Income 2016-2019 (US $Mn, AGR %))
Figure No 160 Incepta Pharmaceuticals Ltd. (Total Company Sales 2016-2019 (US $Mn, AGR %)
Figure No 161 Incepta Pharmaceuticals Ltd. (Net Income 2016-2019 (US $Mn, AGR %))
Figure No 162 Pfizer Inc. (CEO, HQ, Founded, Website)
Figure No 163 Pfizer Inc. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Figure No 164 Pfizer Inc. (Net Income 2016-2019 (US $Mn, AGR %))
Figure No 165 Sanofi S.A. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Figure No 166 Sanofi S.A. (Net Income 2016-2019 (US $Mn, AGR %))
Figure No 167 Serum Institute of India Pvt. Ltd (Total Company Sales 2016-2019 (US $Mn, AGR %))
Figure No 168 Serum Institute of India Pvt. Ltd (Net Income 2016-2019 (US $Mn, AGR %))
Figure No 169 Walvax Biotechnology Co., Ltd. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Figure No 170 Walvax Biotechnology Co., Ltd. (Net Income 2016-2019 (US $Mn, AGR %))
Figure No 171 Merck & Co., Inc. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Figure No 172 Merck & Co., Inc. (Net Income 2016-2019 (US $Mn, AGR %))
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
